Sociodemographic and clinical characteristics of synthetic cannabinoid users in a large psychiatric emergency department in Turkey

References

• Corazza O, Demetrovics Z, van den Brink W, Schifano F. Legal highs’ an inappropriate term for ‘Novel Psychoactive Drugs’ in drug prevention and scientific debate. Int J Drug Policy 2013;24:82–3. doi:10.1016/j.drugpo.2012.06.005.
   PubMed Web of Science ®Google Scholar
• Fattore L, Fratta W. Beyond THC: the new generation of cannabinoid designer drugs. Front Behav Neurosci 2011;5:60.doi:10.3389/fnbeh.2011.00060.
   PubMed Web of Science ®Google Scholar
• Zaurova M, Hoffman RS, Vlahov D, Manini AF. Clinical effects of synthetic cannabinoid receptor agonists compared with marijuana in emergency department patients with acute drug overdose. J Med Toxicol 2016;12:335–40. doi:10.1007/s13181-016-0558-4.
   PubMed Web of Science ®Google Scholar
• Castaneto MS, Gorelick DA, Desrosiers NA, Hartman RL, Pirard S, Huestis MA. Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications. Drug Alcohol Depend 2014;144:12–41. doi:10.1016/j.drugalcdep.2014.08.005.
   PubMed Web of Science ®Google Scholar
• Vandrey R, Dunn KE, Fry JA, Girling ER. A survey study to characterize use of Spice products (synthetic cannabinoids). Drug Alcohol Depend 2012;120:238–41. doi:10.1016/j.drugalcdep.2011.07.011.
   PubMed Web of Science ®Google Scholar
• Macfarlane V, Christie G. Synthetic cannabinoid withdrawal: a new demand on detoxification services. Drug Alcohol Rev 2015;34:147–53. doi:10.1111/dar.12225.
   PubMed Web of Science ®Google Scholar
• Seely KA, Lapoint J, Moran JH, Fattore L. Spice drugs are more than harmless herbal blends: a review of the pharmacology and toxicology of synthetic cannabinoids. Prog Neuropsychopharmacol Biol Psychiatry 2012;39:234–43. doi:10.1016/j.pnpbp.2012.04.017.
   PubMed Web of Science ®Google Scholar
• European Monitoring Centre for Drugs and Drug Addiction. Perspectives on drugs: synthetic cannabinoids in Europe. Lisbon: European Monitoring Center for Drugs and Drug Addiction, 2017.
   Google Scholar
• Hermanns‐Clausen M, Kneisel S, Szabo B, Auwärter V. Acute toxicity due to the confirmed consumption of synthetic cannabinoids: clinical and laboratory findings. Addiction 2013;108:534–44. doi:10.1111/j.1360-0443.2012.04078.x.
   PubMed Web of Science ®Google Scholar
• Papanti D, Schifano F, Botteon G, Bertossi F, Mannix J, Vidoni D, Impagnatiello M, Pascolo‐Fabrici E, Bonavigo T. Spiceophrenia: a systematic overview of “Spice”‐related psychopathological issues and a case report. Hum Psychopharmacol Clin Exp 2013;28:379–89. doi:10.1002/hup.2312.
   PubMed Web of Science ®Google Scholar
• Sherpa D, Paudel BM, Subedi BH, Chow RD. Synthetic cannabinoids: the multi-organ failure and metabolic derangements associated with getting high. J Commun Hosp Intern Med Perspect 2015;5:27540. doi:10.3402/jchimp.v5.27540.
   PubMed Web of Science ®Google Scholar
• Cooper ZD. Adverse effects of synthetic cannabinoids: management of acute toxicity and withdrawal. Curr Psychiatry Rep 2016;18:52. doi:10.1007/s11920-016-0694-1.
   PubMed Web of Science ®Google Scholar
• Spaderna M, Addy PH, D’Souza DC. Spicing things up: synthetic cannabinoids. Psychopharmacology (Berl) 2013;228:525–40. doi:10.1007/s00213-013-3188-4.
   PubMed Web of Science ®Google Scholar
• Castellanos D, Thornton G. Synthetic cannabinoid use: recognition and management. J Psychiatr Pract 2012;18:86–93. doi:10.1097/01.pra.0000413274.09305.9c.
   PubMed Web of Science ®Google Scholar
• Harris CR, Brown A. Synthetic cannabinoid intoxication: a case series and review. J Emerg Med 2013;44:360–6. doi:10.1016/j.jemermed.2012.07.061.
   PubMed Web of Science ®Google Scholar
• Abouchedid R, Hudson S, Thurtle N, Yamamoto T, Ho JH, Bailey G, Wood M, Sadones N, Stove CP, Dines A, et al. Analytical confirmation of synthetic cannabinoids in a cohort of 179 presentations with acute recreational drug toxicity to an Emergency Department in London, UK in the first half of 2015. Clin Toxicol (Phila) 2017;55:338–45. doi:10.1080/15563650.2017.1287373.
   PubMed Web of Science ®Google Scholar
• Winstock AR, Barratt MJ. Synthetic cannabis: a comparison of patterns of use and effect profile with natural cannabis in a large global sample. Drug Alcohol Depend 2013;131:106–11. doi:10.1016/j.drugalcdep.2012.12.011.
   PubMed Web of Science ®Google Scholar
• Palamar JJ, Su MK, Hoffman RS. Characteristics of novel psychoactive substance exposures reported to New York City Poison Center, 2011–2014. Am J Drug Alcohol Abuse 2016;42:39–47. doi:10.3109/00952990.2015.1106551.
   PubMed Web of Science ®Google Scholar
• Tournebize J, Gibaja V, Kahn J-P. Acute effects of synthetic cannabinoids: update 2015. Subst Abus 2017;38:344–66. doi:10.1080/08897077.2016.1219438.
   PubMed Web of Science ®Google Scholar
• Mathai D, Gordon M, Muchmore P, Matorin A, Shah A, Moukaddam N. Paradoxical increase in synthetic cannabinoid emergency-related presentations after a citywide ban: lessons from Houston, Texas. Bull Menninger Clin 2016;80:357–70. doi:10.1521/bumc.2016.80.4.357.
   PubMed Web of Science ®Google Scholar
• Winstock A, Lynskey M, Borschmann R, Waldron J. Risk of emergency medical treatment following consumption of cannabis or synthetic cannabinoids in a large global sample. J Psychopharmacol (Oxford) 2015;29:698–703. doi:10.1177/0269881115574493.
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 5th edition. Washington, DC: American Psychiatric Association, 2013.
   Google Scholar
• Joseph AM, Manseau MW, Lalane M, Rajparia A, Lewis CF. Characteristics associated with synthetic cannabinoid use among patients treated in a public psychiatric emergency setting. Am J Drug Alcohol Abuse 2017;43:117–22. doi:10.1080/00952990.2016.1240799.
   PubMed Web of Science ®Google Scholar
• Hoyte CO, Jacob J, Monte AA, Al-Jumaan M, Bronstein AC, Heard KJ. A characterization of synthetic cannabinoid exposures reported to the National Poison Data System in 2010. Ann Emerg Med 2012;60:435–8. doi:10.1016/j.annemergmed.2012.03.007.
   PubMed Web of Science ®Google Scholar
• Springer YP, Gerona R, Scheunemann E, Shafer SL, Lin T, Banister SD, Cooper MP, Castrodale LJ, Levy M, Butler JC, et al. Increase in adverse reactions associated with use of synthetic cannabinoids—Anchorage, Alaska, 2015–2016. MMWR Morb Mortal Wkly Rep 2016;65:1108–11. doi:10.15585/mmwr.mm6540a4.
   PubMed Web of Science ®Google Scholar
• Bozkurt M, Umut G, Evren C, Karabulut V. Clinical characteristics and laboratory test results of patients admitted to outpatient clinic for synthetic cannabinoid usage. Dusunen Adam 2014;27:328–34. doi:10.5350/DAJPN2014270407.
   Google Scholar
• Öznur T, Öznur H, Bolu A, Çelik C, Özmenler KN. Sociodemographic and clinical features of young adult males using synthetic cannabinoid. J Clin Psy 2018;21:15–23. doi:10.5505/kpd.2018.07269.
   Google Scholar
• Yılmaz K, Yalçın M, Çakmakcı Buyur H, Bektemür G, Egici MT, Leblebici Y. Acil Servise Bonzai Kullanımıyla Başvuran Hastaların Sosyo-Demografik Özelliklerini Retrospektif Olarak Değerlendirilmesi. JAREN/Hemşirelik Akademik Araştırma Dergisi 2015;1:80–5.
   Google Scholar
• Manseau MW, Rajparia A, Joseph A, Azarchi S, Goff D, Satodiya R, Lewis CF. Clinical characteristics of synthetic cannabinoid use in a large urban psychiatric emergency setting. Subst Use Misuse 2017;52:822–5. doi:10.1080/10826084.2016.1263663.
   PubMed Web of Science ®Google Scholar
• Nacca N, Vatti D, Sullivan R, Sud P, Su M, Marraffa J. The synthetic cannabinoid withdrawal syndrome. J Addict Med 2013;7:296–8. doi:10.1097/ADM.0b013e31828e1881.
   PubMed Web of Science ®Google Scholar
• Bassir Nia A, Medrano B, Perkel C, Galynker I, Hurd YL. Psychiatric comorbidity associated with synthetic cannabinoid use compared to cannabis. J Psychopharmacol 2016;30:1321–30. doi:10.1177/0269881116658990.
   PubMed Web of Science ®Google Scholar
• Trecki J, Gerona RR, Schwartz MD. Synthetic cannabinoid-related illnesses and deaths. N Engl J Med 2015;373:103–7. doi:10.1056/NEJMp1505328.
   PubMed Web of Science ®Google Scholar
• Su M, Laskowski L, Hoffman RS. Hyperthermia and severe rhabdomyolysis from synthetic cannabinoids. Am J Emerg Med 2016;34:1690. doi:10.1016/j.ajem.2016.05.015.
   PubMed Web of Science ®Google Scholar
• Kasper AM, Ridpath AD, Arnold JK, Chatham-Stephens K, Morrison M, Olayinka O, Parker C, Galli R, Cox R, Preacely N, Notes F, The F. severe illness associated with reported use of synthetic cannabinoids—Mississippi, April 2015. MMWR Morb Mortal Wkly Rep 2015;64:1121–2. doi:10.15585/mmwr.mm6439a7.
   PubMed Web of Science ®Google Scholar
• Kassai S, Pintér JN, Rácz J, Böröndi B, Tóth-Karikó T, Kerekes K, Gyarmathy VA. Assessing the experience of using synthetic cannabinoids by means of interpretative phenomenological analysis. Harm Reduct J 2017;14:9. doi:10.1186/s12954-017-0138-1.
   PubMed Web of Science ®Google Scholar
• Karaca Z, Wong HS, Mutter RL. Duration of patients' visits to the hospital emergency department. BMC Emerg Med 2012;12:15. doi:10.1186/1471-227X-12-15.
   PubMedGoogle Scholar